Cargando…

Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy

We examined the long-term clinical tolerance and cardiac safety of trastuzumab treatment in ninety-four female patients diagnosed with breast cancer with human epidermal growth factor receptor 2 (HER-2) overexpression. Electrocardiography (ECG) was monitored throughout trastuzumab treatment, and lef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Ping, Dai, Shujun, Ye, Zhimin, Liu, Yajuan, Chen, Zhanhong, Zheng, Yabing, Shao, Xiying, Lei, Lei, Wang, Xiaojia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356780/ https://www.ncbi.nlm.nih.gov/pubmed/27906683 http://dx.doi.org/10.18632/oncotarget.13726

Ejemplares similares

Exploring the concepts and practices of advanced breast cancer treatment: a narrative review
por: Wang, Xiaojia, et al.
Publicado: (2021)

The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer
por: Shao, Xiying, et al.
Publicado: (2015)

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
por: Shao, Xiying, et al.
Publicado: (2021)

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling
por: Chen, Zhanhong, et al.
Publicado: (2019)

Breast liposarcoma with solitary metastasis to the pleura: A case report
por: Lei, Lei, et al.
Publicado: (2017)

Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines
por: Ishii, Taisuke, et al.
Publicado: (2022)

Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study
por: Chen, Zhanhong, et al.
Publicado: (2019)

Clinicopathological Characteristics of Mucinous Breast Cancer: A Retrospective Analysis of a 10-Year Study
por: Lei, Lei, et al.
Publicado: (2016)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors
por: Tanaka, Satoru, et al.
Publicado: (2017)

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China
por: Chen, Zhanhong, et al.
Publicado: (2022)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2020)

Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer
por: Zekri, Jamal, et al.
Publicado: (2023)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
por: Eiger, Daniel, et al.
Publicado: (2020)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Cardiac toxicity of trastuzumab in elderly patients with breast cancer
por: Denegri, Andrea, et al.
Publicado: (2016)

Prognostic Nomogram for Predicting Long-Term Overall Survival of Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Plus Surgery: A Population-Based Study
por: Chen, Mingduan, et al.
Publicado: (2022)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
por: Toi, Masakazu, et al.
Publicado: (2017)

The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer
por: Chen, Keyu, et al.
Publicado: (2022)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
por: Wang, Wei, et al.
Publicado: (2023)

Cardiac toxic effect of radiation therapy in patients receiving adjuvant trastuzumab treatment, as examined by LVEF of echocardiography: an experimental research
por: Khandoozi, Reza, et al.
Publicado: (2023)

Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review
por: Wu, Jiayi, et al.
Publicado: (2022)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment
por: Sun, Yong, et al.
Publicado: (2016)

Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer
por: Kristeleit, Hartmut, et al.
Publicado: (2016)

Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
por: Griffiths, Robert I, et al.
Publicado: (2011)

The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer
por: Miao, Xianyuan, et al.
Publicado: (2021)

Effects of long-term atorvastatin treatment on cardiac aging
por: HAN, LEI, et al.
Publicado: (2013)

Is there a window of opportunity to optimize trastuzumab cardiac monitoring?
por: Rala de Paula, Bruno Henrique, et al.
Publicado: (2022)

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
por: Blondeaux, Eva, et al.
Publicado: (2020)

Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
por: Yin, Wenjin, et al.
Publicado: (2011)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
por: Ito, Mayuko, et al.
Publicado: (2021)

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
por: Geuna, Elena, et al.
Publicado: (2020)

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
por: Xu, Binghe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2cud1flqqjhvhd6od2tjbugmu7